Daily Medication Pearl: Tavneos (avacopan) for Severe Active Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis

Indication: Tavneos is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.

Insight:

• Dosing:The recommended dosage is 30 mg (three 10 mg capsules) twice daily, with food.
• Dosage form: 10 mg capsules
• Adverse events: The most common adverse reactions (≥5%) include nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia.
• Mechanism of action:Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Avacopan blocks C5a-mediated neutrophil activation and migration.
• Manufacturer: ChemoCentryx

References

• Approval Information. Tavneos (Avacopan); ChemoCentryx. October 2021. Accessed November 22, 2021. https://www.chemocentryx.com/wp-content/uploads/2021/10/FINAL-PI-and-Med-Guide-7-Oct-21.pdf
• Tavneos Physician Website. Chemocentryx. Accessed November 22, 2021. https://tavneos.com/hcp/?gclid=EAIaIQobChMIkI659bei9AIVIiCtBh0ywAUpEAAYASAAEgJvTfD_BwE
• ChemoCentryx Taneos US FDA Approval. ChemoCentryx; October 8, 2021. Accessed November 22, 2021. https://ir.chemocentryx.com/static-files/2803ef08-be6b-4000-9975-0a02abe1b5a1